pd 0325901

Mirdametinib (PD325901) is an MEK inhibitor (IC50=0.33 nM) with selective, non-ATP-competitive, and oral activity. Mirdametinib exhibits antitumor activity by inhibiting p-ERK1 2 expression and inducing apoptosis.

(R)-PD 0325901CL, an isomer of PD 0325901CL, acts as a selective inhibitor of mitogen-activated protein kinase kinase (MEK), playing a crucial role in cancer research. It effectively inhibits the growth of cancer cells both in vitro and in vivo.

The main body of PD0325901-O-C2-dioxolane is PD0325901, which is a typical non-ATP-competitive MEK1 2 (mitogen-activated protein kinase) inhibitor occupying a variant-binding pocket near the ATP-binding site, with anticancer effects of decreasing ERK phosphorylation and inhibiting cell proliferation.